Download MendeleyDiazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
Martinez-Viturro, C.M., Trabanco, A.A., Royes, J., Fernandez, E., Tresadern, G., Vega, J.A., Del Cerro, A., Delgado, F., Garcia Molina, A., Tovar, F., Shaffer, P., Ebneth, A., Bretteville, A., Mertens, L., Somers, M., Alonso, J.M., Bartolome-Nebreda, J.M.(2020) J Med Chem 63: 14017-14044
- PubMed: 33197187 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.0c01479
- Primary Citation Related Structures:
7KHS, 7KHV - PubMed Abstract:
O-GlcNAcylation is a post-translational modification of tau understood to lower the speed and yield of its aggregation, a pathological hallmark of Alzheimer's disease (AD). O-GlcNAcase (OGA) is the only enzyme that removes O-linked N -acetyl-d-glucosamine (O-GlcNAc) from target proteins. Therefore, inhibition of OGA represents a potential approach for the treatment of AD by preserving the O-GlcNAcylated tau protein. Herein, we report the multifactorial optimization of high-throughput screening hit 8 to a potent, metabolically stable, and orally bioavailable diazaspirononane OGA inhibitor (+)- 56 . The human OGA X-ray crystal structure has been recently solved, but bacterial hydrolases are still widely used as structural homologues. For the first time, we reveal how a nonsaccharide series of inhibitors binds bacterial OGA and discuss the suitability of two different bacterial orthologues as surrogates for human OGA. These breakthroughs enabled structure-activity relationships to be understood and provided context and boundaries for the optimization of druglike properties.
- Discovery Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75A, 45007 Toledo, Spain.
Organizational Affiliation:
